Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Concerning Apixaban & Venous Thromboembolism, oral apixaban was noninferior to subcutaneous dalteparin for the treatment of Cancer-associated venous thromboembolism without an increased risk of major bleeding.
The clinical phase II trial NCT02048865 showed, that Apixaban therapy resulted in a significantly lower rate of venous thromboembolism than did placebo among intermediate-to-high-risk ambulatory patients with cancer who were starting chemotherapy. The rate of major bleeding episodes was high…